CA Patent

CA2986286A1 — Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid

Assigned to Vertex Pharmaceuticals Inc · Expires 2009-06-11 · 17y expired

What this patent protects

The present invention relates to a combination of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3- methylpyridin-2-yl)benzoic acid and N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3- carboxamide, pharmaceutical compositions thereof, and method…

USPTO Abstract

The present invention relates to a combination of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3- methylpyridin-2-yl)benzoic acid and N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3- carboxamide, pharmaceutical compositions thereof, and methods of treatment therewith.

Drugs covered by this patent

Patent Metadata

Patent number
CA2986286A1
Jurisdiction
CA
Classification
—
Expires
2009-06-11
Drug substance claim
No
Drug product claim
No
Assignee
Vertex Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.